AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2004 APR 14 - (NewsRx.com & NewsRx.net) -- Merix Bioscience, a Durham, North Carolina-based company pioneering therapeutic cancer vaccines, has signed a joint licensing agreement with California-based Geron Corp.
The agreement could propel clinical progress and yield faster commercialization of therapeutic cancer vaccines. Clinical testing utilizing the combined technologies is ongoing at Duke University Medical Center in Durham.
In exchange for 5 million shares of Geron stock, valued at over $43 million, Merix will allow Geron the use of its platform technology for modifying dendritic cells to present 1 or more defined antigens in order to provoke an antitumor immune response. Merix retains co-exclusive rights to use the platform technology with defined antigens other than Geron's telomerase antigen and exclusive rights to use it with total tumor RNA and other uncharacterized antigens.
Merix's platform technology has been validated in several clinical trials at Duke, including the ongoing trial which combines Merix's antigen delivery technology with the telomerase antigen.
"This validation of our technology is especially encouraging as we begin ...
Source: HighBeam Research, Merix Bioscience announces cancer vaccines agreement.